This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The targeted Automated External Defibrillator (AED) program in the Sao Paulo Metro has yielded promising results in improving survival rates for individuals experiencing out-of-hospital cardiac arrest (OHCA) due to ventricular arrhythmias.
Hashtag: #ACC25 European Heart Rhythm Association (EHRA) Congress 2025 Date: 30 March to 1 April 2025 Location: Vienna and online Overview: The yearly gathering of the European Heart Rhythm Association (EHRA) unites scientists, healthcare professionals, and other stakeholders engaged in the global management of arrhythmias.
Diabetes mellitus (DM) is a publichealth problem that continues to grow worldwide. 1 Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting more than 6 million individuals in the United States.2 In the United States the Center for Disease Control and Prevention estimates that it affects 11.6%
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , revealed findings from a company-funded study of real-world data. AFib is the most common type of cardiac arrhythmia and affects more than 6 million people in the United States and nearly 38 million people worldwide.2,3 In: AF Symposium.;
European Heart Rhythm Association (EHRA) Congress Date: April 7-9, 2024 Location: Berlin, Germany and online Overview: The yearly gathering of the European Heart Rhythm Association (EHRA) unites scientists, healthcare professionals, and other stakeholders engaged in the global management of arrhythmias.
1 poses an increased risk to publichealth compared to other circulating variants. Recommended tests, including routine lab work, blood pressure checks, and other tests covered below, are vital to assess heart health. According to doctors, there is no evidence, as per the WHO, that JN.1 Risk posed by JN.1
BackgroundThe Monkeypox Virus (MPOX) has caused a surge in viral infections, leading to the WHO recognizing it as a publichealth emergency of international concern. Myocarditis, an inflammation in the myocardium, can cause dilated cardiomyopathy, acute arrhythmia, and heart failure. Most cases were male and involved chest pain.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. Global epidemiology of atrial fibrillation: An increasing epidemic and publichealth challenge. Food & Drug Administration ( FDA ).
Adaptability and Personalization: Tailored Treatment Plans: ART allows personalized treatment plans that consider individual health, co-existing conditions, and potential drug interactions. Yet the virus remains a significant publichealth concern, with a staggering 40.4 million lives lost to HIV and an estimated 39.0
Introduction Sudden cardiac arrest is a major cause of morbidity and mortality worldwide and remains a major publichealth problem for which better non-invasive prediction tools are needed. Primary preventive therapies, such as implantable cardioverter defibrillators, are not personalized and not predictive.
Abstract Introduction Despite advancements in implantable cardioverter-defibrillator (ICD) technology, sudden cardiac death (SCD) remains a persistent publichealth concern. Time periods were chosen based on the establishment of the Arrhythmia Service in 2011.
While US publichealth authorities have been convinced from the very beginning about how safe and effective the new vaccines are, researchers in other countries with far smaller budgets have been testing that theory. But these rates are in line with a few other large datasets which lends credibility to the estimates.
4 An accompanying editorial 5 notes “Data from COVID-Heart provide reassuring evidence that myocarditis, once predicted to be an emerging publichealth crisis attributable to COVID-19, is relatively uncommon even among hospitalized patients and is less virulent than predicted during the early days of the pandemic.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content